|
108 |
A Risk-based Approach To Filter Integrity Testing Annex 1 Requirements For Biologics DS
|
관리자 |
2025-02-28 |
118 |
|
107 |
Pharmaceutical stability testing: An overview of stability
|
관리자 |
2025-02-28 |
129 |
|
106 |
2024 Trends In FDA Observations For Sterile Drug Manufacturers
|
관리자 |
2025-02-28 |
125 |
|
105 |
Ensuring Repeatable, Viable Surface Sampling In Aseptic Settings
|
관리자 |
2025-02-28 |
119 |
|
104 |
Incubating settle plates: Understanding growth patterns and when things are going wrong
|
관리자 |
2025-02-03 |
247 |
|
103 |
11 Key Contributing Factors For Maintaining Sterility Assurance
|
관리자 |
2025-02-03 |
451 |
|
102 |
Physicochemical Monitoring of Pharmaceutical Water
|
관리자 |
2025-02-03 |
240 |
|
101 |
Audit Readiness For Cell & Gene Therapy Companies
|
관리자 |
2025-02-03 |
247 |
|
100 |
From missing Analysis to Brand Protection Violations - FDA Warning Letter to Canadian Manufacturer
|
sureAssist |
2025-01-02 |
309 |
|
99 |
Risk Analysis in Case of Insufficient Process Validation
|
sureAssist |
2025-01-02 |
284 |
